Astellas Pharma Inc (OP:ALPMF)

13.17 UNCHANGED

Streaming Delayed Price Updated: 2:19 PM EST, Dec 30, 2025 Add to My Watchlist

Price and Volume

Volume	1
Open	13.17
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	13.17
Today's Range	13.17 - 13.17
52wk Range	8.405 - 14.20
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗

November 12, 2025

Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.

Via Benzinga

Why Is Taysha Gene Therapies Stock Falling Friday? ↗

October 17, 2025

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.

Via Benzinga

Performance

YTD	N/A	N/A
1 Month	+2.1%	+2.1%
3 Month	+22.8%	+22.8%
6 Month	+40.6%	+40.6%
1 Year	+33.5%	+33.5%

More News

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗

August 12, 2025

Via Benzinga

Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗

July 10, 2025

Via Benzinga

JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗

March 18, 2025

Via Benzinga

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo ↗

February 11, 2025

Via Benzinga

Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise ↗

January 03, 2025

Via Benzinga

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact ↗

December 31, 2024

Via Benzinga

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗

October 16, 2024

Via Benzinga

Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data ↗

August 05, 2024

Via Benzinga

Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval ↗

May 17, 2024

Via Benzinga

Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study ↗

October 05, 2023

Via Benzinga

Why Is Seagen Stock Trading Higher Today? ↗

September 22, 2023

Via Benzinga

What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? ↗

September 20, 2023

Via Benzinga

Why Shares of Adaptive Biotechnologies Jumped This Week ↗

June 16, 2023

Via The Motley Fool

Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles ↗

June 08, 2023

Via Benzinga

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

June 01, 2023

Via TheNewswire.com

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

June 01, 2023

Via News Direct

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? ↗

May 30, 2023

Via Benzinga

Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories ↗

May 15, 2023

Via Benzinga

Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback ↗

May 15, 2023

Via Benzinga

Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58% ↗

May 01, 2023

Via Benzinga

Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration' ↗

May 01, 2023

Via Benzinga

FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer ↗

April 04, 2023

Via Benzinga

AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners ↗

March 28, 2023

Via Benzinga

Frequently Asked Questions

Is Astellas Pharma Inc publicly traded?

Yes, Astellas Pharma Inc is publicly traded.

What exchange does Astellas Pharma Inc trade on?

Astellas Pharma Inc trades on the OTC Traded

What is the ticker symbol for Astellas Pharma Inc?

The ticker symbol for Astellas Pharma Inc is ALPMF on the OTC Traded

What is the current price of Astellas Pharma Inc?

The current price of Astellas Pharma Inc is 13.17

When was Astellas Pharma Inc last traded?

The last trade of Astellas Pharma Inc was at 12/30/25 02:19 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.